Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaume Capdevila

Showing results (121-130 of 192) with videos related to

Pageof 20
Sort By:
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 27, 2022
Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)Jorge Aparicio, Anna C Virgili Manrique, Jaume Capdevila, et al.
European Journal of Cancer (Oxford, England : 1990)|November 23, 2013
Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinomaJean-Pierre Delord, Josep Tabernero, Rocío García-Carbonero, et al.
Anticancer Research|February 7, 2016
A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine TumoursNicola Fazio, Roberto Buzzoni, Eric Baudin, et al.
BMC Cancer|November 28, 2020
Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term resultsRamón Salazar, Jaume Capdevila, Jose Luis Manzano, et al.
Cell Reports. Medicine|March 21, 2025
A CT-based deep learning-driven tool for automatic liver tumor detection and delineation in patients with cancerMaria Balaguer-Montero, Adrià Marcos Morales, Marta Ligero, et al.
European Journal of Cancer (Oxford, England : 1990)|May 17, 2023
Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumoursJorge Hernando, Maria Roca-Herrera, Alejandro García-Álvarez, et al.
Oncotarget|January 18, 2019
Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinibPaula Jiménez-Fonseca, Miguel Navarro Martín, Alberto Carmona-Bayonas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2021
Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 TrialJoana Vidal, David Casadevall, Beatriz Bellosillo, et al.
Cancer|February 7, 2023
Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 studyDo-Youn Oh, Alain Algazi, Jaume Capdevila, et al.
Radiology. Artificial Intelligence|January 31, 2024
Identification of Precise 3D CT Radiomics for Habitat Computation by Machine Learning in CancerOlivia Prior, Carlos Macarro, Víctor Navarro, et al.
Pageof 20

Showing results (121-130 of 192) with videos related to

Sort By:
Pageof 20
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 27, 2022
Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)Jorge Aparicio, Anna C Virgili Manrique, Jaume Capdevila, et al.
European Journal of Cancer (Oxford, England : 1990)|November 23, 2013
Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinomaJean-Pierre Delord, Josep Tabernero, Rocío García-Carbonero, et al.
Anticancer Research|February 7, 2016
A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine TumoursNicola Fazio, Roberto Buzzoni, Eric Baudin, et al.
BMC Cancer|November 28, 2020
Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term resultsRamón Salazar, Jaume Capdevila, Jose Luis Manzano, et al.
Cell Reports. Medicine|March 21, 2025
A CT-based deep learning-driven tool for automatic liver tumor detection and delineation in patients with cancerMaria Balaguer-Montero, Adrià Marcos Morales, Marta Ligero, et al.
European Journal of Cancer (Oxford, England : 1990)|May 17, 2023
Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumoursJorge Hernando, Maria Roca-Herrera, Alejandro García-Álvarez, et al.
Oncotarget|January 18, 2019
Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinibPaula Jiménez-Fonseca, Miguel Navarro Martín, Alberto Carmona-Bayonas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2021
Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 TrialJoana Vidal, David Casadevall, Beatriz Bellosillo, et al.
Cancer|February 7, 2023
Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 studyDo-Youn Oh, Alain Algazi, Jaume Capdevila, et al.
Radiology. Artificial Intelligence|January 31, 2024
Identification of Precise 3D CT Radiomics for Habitat Computation by Machine Learning in CancerOlivia Prior, Carlos Macarro, Víctor Navarro, et al.
Pageof 20